Why Precision Medicine?

 

  • A 2016 study showed that the percentage of cancer patients who achieved tumor shrinkage doubles when prescribed treatments matched to their genomic profile.

  • Comprehensive genomic profiling enables physicians to find more treatment options and select the most suitable treatment based on  genomic characteristics.

  • Using ACTOnco®+ comprehensive genomic profiling, 83.9% of the patients found corresponding treatment solutions.

 

% Achieved Tumor Shrinkage


Conventional Medicine
One-size-fits-all

Precision Medicine
Genotype-matched and personalized

Source: Genome Medicine (2016) 8:109

What We Offer

Comprehensive Genomic Profiling

ACTOnco®+ analyzes 440 genes to help physicians find more treatment options and identify the most suitable therapies. Treatment evaluation includes targeted therapy, immunotherapy, hormone therapy and chemotherapy.

Liquid Biopsy for Cancer Monitoring

ACTMonitor™analyzes tumor DNA circulating in blood stream to provide physicians with real-time monitoring of drug resistance, early detection of cancer recurrence and evaluation of treatment responses.

 

 

Patient Stories

Mr. Yu, Taiwan

Cancer completely changed my perspective on life. Now I focus on enjoying life and trying to make the most out of every day. I’m glad my doctor told me about comprehensive genomic profiling that found more treatment options for me.

 

Mr. Yu, Taiwan
Stage 4 Lung Cancer Survivor

More Patient Stories

About ACT Genomics

ACT Genomics empowers physicians with evidence-based genomic insights and partners with biopharma to accelerate drug development through biomarker discovery, patient stratification and comprehensive cancer molecular analysis. Our headquarters and CAP-accredited laboratory are located in Taiwan with offices in Singapore, Hong Kong and Japan.

 

83.9%
Found Treatment Solutions

75
Collaborating Hospitals

14
Biopharma & Research Partners

News

 

Canon Medical partners with ACT Genomics!

Canon Medical System Corporation officially acquired ACT Genomics’ joint venture company in Japan, ACTmed! ACT Genomics will transfer its clinical NGS technology and help operate cancer genomic profiling service in Japan.

Get to know more about ACT Genomics

E-newsletters

2018.Aug.31th

ACT Genomics September Enewsletter

2018 VOL.09

See More

Keep in Touch

Subscribe to ACT Genomics Newsletter to be connected to the latest precision medicine